Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Global experience with ondansetron and future potential

M E Butcher1

  • 1Glaxo Group Research, Greenford, Middlesex, UK.

Oncology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.

Cancer treatment reviews·1990
Same author

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Cancer chemotherapy and pharmacology·1990
Same author

The emergence of resistance of Pseudomonas aeruginosa in patients treated with ceftazidime.

Scandinavian journal of infectious diseases·1987
See all related articles

Ondansetron effectively controls nausea and vomiting from chemotherapy and radiotherapy. This anti-emetic is well-tolerated, cost-effective, and improves patient quality of life.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Oncology Supportive Care

Background:

  • Ondansetron, synthesized in 1983, has been administered in over 4 million patient treatments.
  • Clinical trials involving over 15,000 patients confirm its efficacy and tolerability.
  • It offers convenient administration options, including intravenous and oral formulations.

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of ondansetron in managing chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV).
  • To assess the cost-effectiveness and impact on quality of life compared to traditional anti-emetics.
  • To explore its utility in other clinical settings, such as postoperative nausea and vomiting (PONV) and cisplatin-induced delayed emesis.

Main Methods:

  • Clinical trials encompassing diverse patient populations (adults and children) and treatment scenarios.

Related Experiment Videos

  • Comparative studies assessing quality of life against metoclopramide.
  • Cost-effectiveness analyses considering treatment failure costs of alternative anti-emetics.

    • Main Results:

    • Ondansetron demonstrates significant efficacy and good tolerability across various clinical settings and treatment durations.
    • It provides effective control of acute emesis with single intravenous doses and twice-daily oral therapy.
    • Studies indicate improved quality of life and cost-effectiveness compared to metoclopramide and traditional anti-emetics.

    Conclusions:

    • Ondansetron represents a major advancement in controlling nausea and vomiting associated with chemotherapy and radiotherapy.
    • Its efficacy, tolerability, convenience, and cost-effectiveness support its widespread clinical use.
    • Ongoing research continues to explore its full therapeutic potential in diverse emetogenic conditions.